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Abstract: Next-generation sequencing has revolutionized rare disease diagnostics, but many patients
remain without a molecular diagnosis, particularly because many candidate variants usually survive
despite strict filtering. Exomiser was launched in 2014 as a Java tool that performs an integrative
analysis of patients’ sequencing data and their phenotypes encoded with Human Phenotype Ontology
(HPO) terms. It prioritizes variants by leveraging information on variant frequency, predicted
pathogenicity, and gene-phenotype associations derived from human diseases, model organisms,
and protein–protein interactions. Early published releases of Exomiser were able to prioritize
disease-causative variants as top candidates in up to 97% of simulated whole-exomes. The size of the
tested real patient datasets published so far are very limited. Here, we present the latest Exomiser
version 12.0.1 with many new features. We assessed the performance using a set of 134 whole-exomes
from patients with a range of rare retinal diseases and known molecular diagnosis. Using default
settings, Exomiser ranked the correct diagnosed variants as the top candidate in 74% of the dataset
and top 5 in 94%; not using the patients’ HPO profiles (i.e., variant-only analysis) decreased the
performance to 3% and 27%, respectively. In conclusion, Exomiser is an effective support tool for rare
Mendelian phenotype-driven variant prioritization.
Keywords: whole-exome sequencing; whole-genome sequencing; rare disease; variant prioritization;
human phenotype ontology; phenotypic similarity; bioinformatics; inherited retinal disease
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1. Introduction
Despite the tremendous advances brought by next-generation sequencing to the field of rare
Mendelian gene discovery and diagnostics, many challenges remain [1,2], and this is reflected in
limited diagnostic yield. A recent review of the results of whole-exome sequencing (WES) in rare
pediatric disorders reported variable diagnostic rates depending on the diagnosis. Positive results
were reported in 17% for renal disease, 56% for non-syndromic deafness and inherited retinal disease
(IRD), and 76% for ciliary dyskinesia [3]. Several limitations of high-throughput sequencing still exist
that may impact the diagnostic yield. These include the yet incomplete coverage affecting especially
short-read sequencing, the nonexistence of a de facto standard calling algorithm for copy-number
variants (CNVs), or the challenges in filtering and interpreting short tandem repeats with no known
disease association [4]. Another major reason why a disorder remains unsolved after undergoing
next-generation sequencing is the complexity of the interpretation of the wealth of variants found,
which is further hindered by the incomplete knowledge on gene functions [4]. For example, an
individual WES experiment typically identifies tens of thousands of variants (when compared to the
reference genome). Of these, roughly 10,000 may be predicted to result in nonsynonymous amino acid
changes, to alter conserved splice sites, or to represent small insertions or deletions (indels). Strict
frequency filtering is generally applied to discard common variants (seen in publicly available and/or
in-house sequencing datasets) that would not explain a rare disease phenotype and/or those variants
that would not fit the expected mode of inheritance. Nevertheless, additional criteria are usually
needed to refine the number of possible candidate variants. On the other hand, although selecting
variants that are extremely rare or absent in population-based reference datasets may be helpful in
a first step of the analysis, using very low frequency cutoffs may remove clinically relevant variants
and may lead to false negative findings, especially in hard to solve cases [5]. More complex statistical
frameworks that account for disease prevalence, genetic and allelic heterogeneity, inheritance mode,
penetrance, and sampling variance in reference datasets have been recently suggested for a more
effective frequency-based variant filtering [5,6].
A growing number of in silico (freely available) computational tools have been developed to
predict the pathogenicity of missense variants [7,8]. These include (i) function-prediction methods
based on the likelihood of a given missense variant causing pathogenic changes in protein function
(e.g., FATHMM [9], fitCons [10], LRT [11], MutationAssessor [12], MutationTaster [13], PolyPhen-2 [14],
PROVEAN [15], SIFT [16], and VEST3 [17]), (ii) conservation methods that use multiple alignments
to measure the degree of conservation at a given nucleotide site (e.g., GERP++ [18], phastCons [19],
phyloP [20], and SiPhy [21]), and (iii) ensemble methods that integrate information from multiple
component methods (e.g., CADD [22], DANN [23], Eigen [24], FATHMM-MKL [25], GenoCanyon [26],
M-CAP [27], MetaLR [28], MetaSVM [28], REVEL [29], GAVIN [30], and MPC [31]. Other more
recent methods concern a tailored use of deep neural networks (e.g., MVP [32] and PrimateAI [33]).
Overall, there is a lack of agreement of the different methods in classifying variants as benign or
disease-causing. A recent study thoroughly assessed the performance of 23 of these methods in
evaluating 3 independent benchmarking datasets, including clinical variants from ClinVar database
(https://www.ncbi.nlm.nih.gov/clinvar), somatic variants, and experimentally evaluated variants [8].
The results demonstrated that the specificities were lower than the sensitivities for most methods
across datasets, suggesting the need for more stringent cutoff values to distinguish pathogenic variants.
For example, using the ClinVar dataset, the specificities ranged from 35% to 90% (median, 65%) and
the sensitivities ranged from 51% to 96% (median, 88%). Altogether, the study confirmed that using
variant prioritization methods based purely on putative sequence variant pathogenicity is expected to
generate many false positive candidates.
In order to overcome these difficulties, another generation of (freely available) tools have
been developed that incorporate a rare disease patient’s phenotype into the interpretation of their
sequencing data. These include eXtasy [34], BiERapp [35], Phen-Gen [36], Exomiser [37], Phevor [38],
PhenoVar [39], PhenIX [40], OVA [41], Phenolyzer [42], wANNOVAR [43], OMIM Explorer [44],
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QueryOR [45], GenIO [46], DeepPVP [47], MutationDistiller [48], Phrank [49], Xrare [50], PhenoPro [51],
and Phenoxome [52]. Such phenotype-driven prioritization tools leverage existing genotype to
phenotype information from various databases in order to prioritize candidate variants in those genes
that are likely to be more relevant to the patient’s phenotype. In other words, these methods try to
automate many of the manual interpretation steps that clinicians and molecular geneticists usually
perform to identify those genes that show connections with the phenotype of a patient. Although
these methods vary in many methodological and technical aspects, they all require that the patient
phenotypic information is encoded into terms from the Human Phenotype Ontology (HPO) [53–56] to
make it readable and interpretable for computational analysis. The HPO is a flagship product of the
Monarch Initiative (https://monarchinitiative.org/), a National Institutes of Health (NIH)-supported
international consortium for semantic integration of biomedical and model organism data with the
ultimate goal of improving biomedical research. The ontology currently contains over 13,000 terms
describing human phenotypic abnormalities and over 156,000 annotations to hereditary diseases and
has become the de facto standard for deep phenotyping in the field of rare disease [53].
Exomiser was among the first bioinformatics tools of its kind, published in 2014 [37] as a freely
available Java program. It requires as input (i) a variant call format (VCF) file with the called variants of
a rare disease patient (or optionally a multi-sample VCF and pedigree (PED) file if family members have
also been sequenced) and (ii) a set of HPO terms to describe the corresponding patient’s phenotype.
A range of user-defined variant filtering criteria can be applied based on JANNOVAR [57] functional
annotation, frequency, and expected inheritance pattern. The filtered variants are then prioritized
according to a variant score based on their rarity and in silico algorithm-predicted pathogenicity,
combined with a gene-specific phenotype score. In the original release [37], the phenotype score was
calculated based on the semantic similarity (obtained via the PhenoDigm algorithm [58]) between
the user-provided HPO-encoded patient’s phenotype and the phenotypic annotations of orthologous
genes in mouse model organisms. Subsequently, this has been extended to cover also the phenotypic
annotations of genes in known human diseases, orthologs in zebrafish model organisms, and phenotypes
of protein–protein associated neighbors [59,60] (Figure 1). Furthermore, Exomiser now allows both
coding and noncoding variant prioritization from whole-genome sequencing data [61].
Exomiser was able to prioritize causative variants as top candidates in up to 97% of 10,000
simulated rare disease whole-exomes (based on 28,516 known disease-causing mutations from the
human gene mutation database (HGMD, http://www.hgmd.org) and on 1092 whole-exome VCF files
from the 1000 Genomes Project) [59]. Software performance statistics on real patient whole-exome
datasets published so far remain very limited; eleven previously identified disease-causing variants
from real patient data were ranked in the top 7 hits of their respective lists by Exomiser and 6 of 11
were ranked first [59]. Since its first published releases, Exomiser has been updated multiple times
with a number of improved and additional features. The aims of this report were i) to present the latest
release of Exomiser (version 12.0.1) with a description of the main newly added features and ii) to
show the corresponding software performance statistics on a real patient whole-exome dataset from
134 individuals affected by rare IRD who had previously received a molecular diagnosis based on the
analysis of their NGS data. Remarkably, Exomiser effectively prioritized the correct disease-causing
variants among the top 5 candidates for most of the patients (i.e., 94%). We recommend adopting
Exomiser to guide and accelerate the typically complex and time-consuming, multidisciplinary work
required to prioritize candidate variants and to provide molecular diagnoses in rare Mendelian
disease-sequencing efforts.
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Figure 1. Overview of the Exomiser workflow analysis: The diagram depicts the two main steps in
an Exomiser a alysis: (a) variant filtering and (b) variant prioritizati n. A single-sample variant call
format (VCF) file and corresponding list of Human Phenoty e Ontol gy (HPO) terms are mandatory
inputs. If a multi-sample VCF file (from a nuclear family) is used in the analysis, the user must provide
a corresponding pedigree file. In the filtering step, variants are filtered according to type of variant,
allele frequency in selected databases, and mode of inheritance as per user-defined options and values.
In the prioritization step, a variant score is calculated based on allele frequency and pathogenicity as
predicted by user-defined in silico algorithms, together with a gene-specific phenotype score based
on the semantic similarity of the patient’s HPO terms and phenotypic annotation in known human
disease gene, mouse, zebrafish and protein–protein interaction databases. Finally, the Exomiser score is
obtained from the variant score and phenotypic score within a logistic regression classifier framework
and used for variant prioritization. PED: Pedigree, OMIM: Online mendelian inheritance in man, IMPC:
International mouse phenotyping consortium, STRING: Search tool for the retrieval of interacting
genes/proteins.
2. Materials and Methods
2.1. Real Patient Whole-Exome Dataset with Known Molecular Diagnosis
We evaluated Exomiser software performance using a real patient whole-exome dataset with
known molecular diagnosis obtained from a number of next-generation sequencing studies that
were conducted at Moorfields Eye Hospital and the University College London (UCL) Institute of
Ophthalmology (London, UK) approximately over four years (2011–2015) [62]. The dataset was
extracted from the overall patient cohort of 340 individuals that had been diagnosed with IRD by
a consultant ophthalmologist and that had undergone WES. All patients had been sequenced as
singletons, except for six probands where one or both parents were also sequenced. The patient cohort
was enriched for rare genetic causes of IRD (many of which have been published over the years). Cases
were selected for their likelihood of harbouring a novel discovery based on many features, including
family consanguinity/number of affected siblings in recessive families, prior negative testing for the
Asper Ophthalmics chip (Asper Biogene, Tartu, Estonia), candidate gene sequencing or the Manchester
105-gene diagnostic panel, unusual phenotype/clinical history, prior single nucleotide polymorphism
linkage/homozygosity mapping, absence of typical clinical features of ABCA4-retinopathy, or other
(near) monogenic diseases (e.g., X-linked retinoschisis, RS1, or choroideremia, CHM). A total of 134
IRD patients that had received a molecular diagnosis (i.e., “solved” patients) at the time of the data
extraction based on single nucleotide variants (SNVs) and/or indels (as present in their respective VCF
files) were included in the Exomiser software performance assessment. Twelve additional patients
with a molecular diagnosis that involved CNVs could not be used due to the current software inability
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of incorporating CNVs into the analysis. The molecular diagnosis of the IRD patients had been based
on the analysis and interpretation of the patient WES data performed by various clinicians, scientists,
and analysts without using Exomiser. Where possible, diagnosed variants, including compound
heterozygous variants, had been validated in an accredited clinical diagnostic laboratory. Familial
segregation analysis had been performed where appropriate to reach a diagnostic conclusion. The
study protocols adhered to the tenets of the Declaration of Helsinki and received approval from the
local ethics committee (MOOA1016, 13/EE/0325). Written informed consent was obtained from all
participants, or their parents, before their inclusion in the study.
Table 1 shows the frequency distribution of the clinical diagnosis (assigned before performing
WES), with the majority of the patients being diagnosed with retinitis pigmentosa (27%), Leber
congenital amaurosis (19%), macular dystrophy (12%), and cone-rod dystrophy (10%). Following WES,
for most of the patients, the molecular diagnosis was based either on a homozygous genotype (72
out of 134) or a compound heterozygous genotype (39) (Table 2). The full list of disease-associated
genes and variants for the 134 IRD solved patients is shown in Table S1. Mutations in 60 genes were
identified to be disease-causing among the 134 IRD patients (Figure S1), with variants in USH2A
accounting for 7% of the dataset, variants in RPGR and ABCA4 accounting for 6%, and variants in
GUCY2D accounting for 5%. The dataset exhibited both genetic and phenotypic heterogeneity (Figure
S2). For example, variants in four different diagnosed genes (ATF6, CNGB3, GNAT2, and POC1B)
were associated to the same clinical diagnosis achromatopsia (genetic heterogeneity), while variants in
CRB1 were found in patients who had been diagnosed with Leber congenital amaurosis and retinitis
pigmentosa (phenotypic heterogeneity). In the cases of CLN3, COL18A1, HPS6 and SRD5A3, the
corresponding patients had been initially diagnosed with non-syndromic IRD and, after further clinical
examination, following the analysis of their WES data, were assigned to a syndromic IRD diagnosis
(Batten disease, Knobloch syndrome, Hermansky-Pudlak syndrome, and SRD5A3-related congenital
disorder of glycosylation, respectively). The set of disease-associated genes in this cohort included both
established and more recently identified IRD genes (for a continuously updated list of IRD-associated
genes, see https://sph.uth.edu/retnet/).
Table 1. Frequency distribution of the clinical diagnosis in the inherited retinal disease (IRD)
patient dataset.
Clinical Diagnosis a N %
Retinitis pigmentosa (RP) 36 26.9
Leber congenital amaurosis (LCA) 25 18.7
Macular dystrophy (MD) 16 11.9
Cone-rod dystrophy (CRD) 14 10.4
Early onset retinal dystrophy (EORD) 9 6.7
Usher syndrome type II (USH2) 8 6.0
Achromatopsia (ACHM) 6 4.5
Congenital stationary night blindness (CSNB) 5 3.7
Retinal dystrophy (RD) 3 2.2
Usher syndrome type I (USH1) 2 1.5
Stargardt disease (STGD) 2 1.5
Occult macular dystrophy (OCMD) 1 0.7
Benign fleck retina (BFR) 1 0.7
Coloboma (COLOB) 1 0.7
Familial exudative vitreoretinopathy (FEVR) 1 0.7
Foveal hypoplasia (FH) 1 0.7
Myopia and deafness (Stickler syndrome)
(STICKL) 1 0.7
Ocular albinism (OALB) 1 0.7
Optic atrophy (OATR) 1 0.7
Total 134 100.0
a As assigned by a consultant ophthalmologist before performing whole-exome sequencing.
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Table 2. Frequency distribution of the genotype of the “solved” molecular diagnoses in the IRD
patient dataset.
Genotype N %
Homozygote 72 53.7
Compound heterozygote 39 29.1
Heterozygote 13 9.7
Hemizygote a 10 7.5
Total 134 100.0
a Male patients with diagnosed variants on the X chromosome.
2.2. Human Phenotype Ontology (HPO)-Encoded Clinical Diagnoses
In order to overcome the laborious process of acquiring patient-specific deep phenotypes to
translate into HPO terms, each clinical diagnosis was assigned a parsimonious, fixed list of most
representative HPO terms (from one single term to six terms) by three ophthalmologists with expertise
in IRD diagnosis (Table S2). The graphic visualization of the HPO terms for Leber congenital amaurosis
as subgraphs of the full ontology are presented in Figure 2. Leber congenital amaurosis was annotated
to four HPO terms, i.e., retinal dystrophy (HP:0000556), visual impairment (HP:0007758), undetectable
electroretinogram (HP:0000550), and nystagmus (HP:0000639), and, implicitly, to the parental terms in
the ontology, i.e., phenotypic abnormality, eye, and eye morphology for retinal dystrophy and phenotypic
abnormality, eye, and eye physiology for the other 3 terms. The HPO graphic visualization for all the
clinical diagnoses observed in the IRD patient dataset is depicted in Figure S3.
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either hg19 or hg38 genomic coordinates. Analysis of mitochondrial data is now possible (assuming
mitochondrial variants are called in the input VCF file, they will be filtered and interpreted in
the same manner as nuclear variants). In addition to the 1000 Genomes Project [63], the National
Heart, Lung, and Blood Institute Grand Opportunity (NHLBI GO) Exome Sequencing Project (ESP,
http://evs.gs.washington.edu/EVS), and the Exome Aggregation Consortium (ExAC) [64] datasets
used in earlier software releases, variant frequency data used in the filtering step are now taken
from additional large sequencing studies, including Trans-Omics for Precision Medicine (TOPMed)
(https://www.nhlbiwgs.org), UK10K [65], and Genome Aggregation Database (gnomAD) [66]. Together
with publicly available datasets, the user can additionally specify an in-house dataset of variant allele
frequency (LOCAL) for variant filtering. The maximum minor allele frequency (MAF) seen across all
the selected datasets is used for comparison with the chosen allele frequency cutoff; the allele frequency
cutoffs can now be tailored to each selected mode of inheritance (autosomal dominant, AD; autosomal
recessive, AR; X-linked dominant, XD; X-linked recessive, XR; and MT) and the user can decide to
run the analysis for multiple modes of inheritance simultaneously. For AR and XR, the variant allele
frequency cutoffs can be specified for homozygous and compound heterozygous genotypes separately.
After variant filtering by Phred quality score (option qualityFilter), type of variant (option
variantEffectFilter), and allele frequency by mode of inheritance (options FrequencyFilter, frequencySources
and inheritanceModes), Exomiser assigns each remaining filtered variant a “variant score” (from 0
for benign to 1 for pathogenic) that is the product of the variant frequency score and the variant
pathogenicity score (Figure 1). The variant frequency score between 0 and 1 is now calculated as
1.13533 − (0.13533 · e100f ) (where f is the maximum MAF seen in the selected variant databases in
the filtering settings) and is set to 0 if f is > 2 and to 1 if f is equal to 0. The variant pathogenicity
score is defined as the maximum of the pathogenicity scores selected by the user (after transforming
and/or normalizing them to lie between 0 for benign and 1 for pathogenic). In the earlier published
software releases [37,59], the user could select the pathogenicity scores (option pathogenicitySources)
among PolyPhen-2 [14], MutationTaster [13], and SIFT [16]; the ensemble method CADD [22,67] was
added later, followed by the more recent ensemble pathogenicity scores M_CAP [27], REVEL [29],
and MPC [31], together with the latest deep neural network methods MVP [32] and PrimateAI [33],
all available from software version 12.0.0. For frameshift, nonsense, canonical splice acceptor/donor,
stop-loss, and start-loss variants, the pathogenicity scores are fixed and have been increased from 0.95
to the maximum score of 1 to reflect the clinical interpretation of these variant consequences; splice
region variants are assigned score 0.8. When no pathogenicity data for a certain allele is present in the
specified pathogenicity sources, Exomiser uses a preset value based on the most pathogenic, predicted
variant consequence for all transcripts overlapping that genomic position. Another latest feature
enables flagging variants on a whitelist and bypassing of the variantEffectFilter and frequencyFilter
options. By default, the whitelist consists of ClinVar (https://www.ncbi.nlm.nih.gov/clinvar) variants
listed as “Pathogenic” or “Likely_pathogenic” and with a review status of “criteria provided, single
submitter” or better [68]. Indeed, the user can edit the variant whitelist (i.e., an openly available tabix
indexed file) by adding any variants they want to keep, bypassing any filtering settings. Finally, in the
case of a candidate compound heterozygous genotype, the final variant score is obtained from the
average of the two corresponding variant scores.
As in earlier software releases, if the hiPhivePrioritiser option is enabled, the variant prioritization
step is active and each gene containing any filtered variant(s) receives a “phenotype score” (from 0 to
1) (Figure 1). The gene-specific phenotype score is based on the best semantic similarity (calculated via
the PhenoDigm algorithm [58]) between the user-provided patient’s phenotype (encoded as a set of
HPO terms) and the phenotypic annotation of any known gene-associated phenotypes in: (i) a human
disease (as curated in OMIM [69] and Orphanet [70]), (ii) a mouse model (as curated in the Mouse
Genome Informatics (MGI) [71] and International Mouse Phenotypic Consortium databases; IMPC,
www.mousephenotype.org), (iii) a zebrafish model (as curated in the Zebrafish Model Organism
Database, ZFIN [72]) for the candidate gene; or iv) a human/mouse/zebrafish model for a neighboring
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gene in the interactome (obtained via STRING [73] analysis). If the omimPrioritiser option is enabled, in
case a phenotype match with a known human disease gene is found, Exomiser checks whether the
patient’s candidate genotype is consistent with the reported OMIM disease mode of inheritance; if there
is inconsistency, the corresponding phenotype score is halved. Finally, the variants with the highest
variant score within each candidate gene are flagged as “contributing” variants and their corresponding
variant score is combined with the gene-specific phenotype score into the Exomiser score (from 0 to 1).
The Exomiser score is obtained using a logistic regression classifier on a training set of 10,000 disease
and 10,000 benign variants with a ten-fold cross-validation as previously described [37,59] and further
optimized in latest software releases (Figure 1).
Other recent changes include the split of the internal Exomiser database into a variant and a
phenotypic database to allow for more frequent and smaller updates; the variant database now stores
information on over 300 million variants for each assembly in a new highly compressed data format
that enables much smaller on-disk footprint with minimal loss of read performance.
2.4. Software Analysis Settings
Exomiser was run on each single-patient VCF file in combination with their respective
HPO-encoded clinical diagnosis; the IRD patient dataset comprised only unrelated patients and
therefore no PED file was required. We repeated the analysis on the same patient dataset under
a variety of settings intended: to mimic clinical diagnostic conditions, to allow comparison with
previously published results on simulated data, to assess the value of integrating the HPO patients’
profiles in the variant prioritization analysis, and to gain insights into some of the newly added
software features. Ensembl transcript annotation was used across all the analysis settings, together
with the same options and values for the filtering step (Table 3). The allele frequency cutoffs per each
mode of inheritance were set to match the filtering criteria of the bioinformatics pipeline that had
been used to solve the cases. As an optional LOCAL in-house dataset for variant filtering, we used
UCLex [74], an exome database of about 4500 whole-exomes collected at University College London
(UK) from various research groups since 2012, to which the IRD patients included in this analysis
belong to. The performance of Exomiser on the IRD patient dataset was assessed using the following
eight analysis settings (Table 3):
1) DEFAULT: the Exomiser score was obtained from the variant score based on allele frequency
(as defined in the filtering step) and the original pathogenicity algorithms PolyPhen-2 [14],
MutationTaster [13], and SIFT [75] using
pathogenicitySources: [POLYPHEN, MUTATION_TASTER, SIFT],
plus the gene-specific phenotype score, using
hiPhivePrioritiser: {},
and
omimPrioritiser: {}.
2) VAR-ONLY: as in analysis setting 1) but using only the variant score, i.e., hiPhivePrioritiser and
omimPrioritiser were disabled (to gain insights into any added value of using the phenotype score in
the Exomiser calculation);
3)–8) CADD/REVEL/MPC/M_CAP/MVP/PRIMATE-AI: as in analysis setting 1) using both the
variant score and the phenotype score but making use of only one of the newly added pathogenicity
algorithms at a time to calculate the variant score, e.g., pathogenicitySources: [CADD] (to gain insights
into the behavior of the newly added pathogenicity algorithms).
Exomiser was run on the Queen Mary University’s Apocrita HPC facility (supported by
QMUL Research-IT (http://doi.org/10.5281/zenodo.438045) using the following command-line per each
single-sample analysis and each of the eight different analysis YML files shown in Table 3:
java -Xms2g -Xmx4g -jar exomiser-cli-12.0.1.jar –analysis AnalysisFilename.yml
with Java version 1.8, Exomiser variant and phenotype data version 1902, CADD data version 1.4
(Genome build GRCh37/hg19; https://cadd.gs.washington.edu/).
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Table 3. Exomiser analysis YML files (.yml) using different settings. Bold stands for analysis setting names and italics for functions.
Analysis YML File
1. DEFAULT
analysis:
genomeAssembly: hg19
vcf : path-to-VCF-file
hpoIds: [comma-separated-list-of-HPO-terms]
inheritanceModes: {
AUTOSOMAL_DOMINANT: 0.1,
AUTOSOMAL_RECESSIVE_HOM_ALT: 0.5,
AUTOSOMAL_RECESSIVE_COMP_HET: 2.0,
X_DOMINANT: 0.1,
X_RECESSIVE_HOM_ALT: 0.5,
X_RECESSIVE_COMP_HET: 2.0,
}
analysisMode: PASS_ONLY
frequencySources: [LOCAL, THOUSAND_GENOMES, TOPMED, UK10K, ESP_AFRICAN_AMERICAN, ESP_EUROPEAN_AMERICAN, ESP_ALL,
EXAC_AFRICAN_INC_AFRICAN_AMERICAN, EXAC_AMERICAN, EXAC_SOUTH_ASIAN, EXAC_EAST_ASIAN, EXAC_FINNISH,
EXAC_NON_FINNISH_EUROPEAN, EXAC_OTHER, GNOMAD_E_AFR, GNOMAD_E_AMR, GNOMAD_E_EAS, GNOMAD_E_FIN,
GNOMAD_E_NFE, GNOMAD_E_OTH, GNOMAD_E_SAS, GNOMAD_G_AFR, GNOMAD_G_AMR, GNOMAD_G_EAS, GNOMAD_G_FIN,
GNOMAD_G_NFE, GNOMAD_G_OTH, GNOMAD_G_SAS]
pathogenicitySources: [POLYPHEN, MUTATION_TASTER, SIFT]
steps: [
qualityFilter: {minQuality: 30.0}
variantEffectFilter: {
remove: [FIVE_PRIME_UTR_EXON_VARIANT, FIVE_PRIME_UTR_INTRON_VARIANT, THREE_PRIME_UTR_EXON_VARIANT,
THREE_PRIME_UTR_INTRON_VARIANT, NON_CODING_TRANSCRIPT_EXON_VARIANT, UPSTREAM_GENE_VARIANT,
INTERGENIC_VARIANT, REGULATORY_REGION_VARIANT, CODING_TRANSCRIPT_INTRON_VARIANT,
NON_CODING_TRANSCRIPT_INTRON_VARIANT, DOWNSTREAM_GENE_VARIANT]
},
frequencyFilter: {maxFrequency: 2.0},
pathogenicityFilter: {keepNonPathogenic: true},
inheritanceFilter: {},
omimPrioritiser: {},
hiPhivePrioritiser: {}
]
2. VAR-ONLY
As per DEFAULT, but
without
omimPrioritiser: {} and
hiPhivePrioritiser: {}
3. CADD
As per DEFAULT, but with
pathogenicitySources:
[CADD]
4. REVEL
As per DEFAULT, but with
pathogenicitySources:
[REVEL]
5. MPC
As per DEFAULT, but with
pathogenicitySources: [MPC]
6. M_CAP
As per DEFAULT, but with
pathogenicitySources:
[M_CAP]
7. MVP
As per DEFAULT, but with
pathogenicitySources: [MVP]
8. PRIMATE-AI
As per DEFAULT, but with
pathogenicitySources:
[PRIMATE-AI]
LOCAL is University College London exome database (UCLex) [74]. Ensembl transcript annotation was used across all the analysis settings.
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2.5. Software Performance Evaluation and Statistical Analysis
To assess the performance of Exomiser on the IRD patient dataset, we noted the rank at which the
software outputs the correct diagnosed disease variant(s) in each single-patient output (.tsv) file for the
corresponding solved mode of inheritance (i.e., AR for the homozygous and compound-heterozygous
solved genotypes, AD for the heterozygote solved genotypes, and XR for the hemizygous solved
genotypes with variants on the X chromosome) (Table S1). Equally scoring gene-variant observations
(ties) were resolved by assigning the corresponding average rank. The pairwise agreement among the
Exomiser ranking results between DEFAULT and VAR-ONLY settings and between DEFAULT and each
of the six single pathogenicity algorithm-based settings, i.e., CADD, REVEL, MPC, M_CAP, MVP, or
PRIMATE-AI, were evaluated using the Wilcoxon signed rank test for paired data. We also categorized
the ranking results for the causative variants into five mutually exclusive disease-causing ranking bins:
“Top”, “2–5”, “6–10”, “>10”, and “Filtered out/Not prioritized” (the latter being any disease-causing
variant(s): failed to be kept in during the filtering step/not selected as “contributing” variants to the
final Exomiser score during the prioritization step) and calculated the corresponding Cohen’s kappa
coefficient (κ). Cohen’s kappa values were interpreted according to Landis and Koch’s guidelines (i.e., κ
< 0.00 as “poor” agreement, 0.00–0.20 as “slight”, 0.21–0.40 as “fair”, 0.41–0.60 as “moderate”, 0.61–0.80
as “substantial”, and 0.81–1 as “almost perfect” agreement) [76]. The nonparametric Stuart–Maxwell
test was then used to assess the marginal homogeneity of the five ranking bins simultaneously. All the
statistical analyses were conducted using Stata software (version 14.2; StataCorp LLC, College Station,
TX, USA) signrank, symmetry, and kap commands; the HPO graphic visualization was carried out using
R version 3.5.3 within Rstudio version 1.1.442 (ontologyIndex and ontologyPlot packages [77]).
2.6. Whole-Exome Sequencing Data
Genomic DNA was purified from peripheral blood mononuclear cells for WES. WES was
performed independently or as part of the National Institute for Health Research BioResource—Rare
Disease study (NIHR BR-RD) as previously described [78]. Samples were analyzed as part of the
UCLex WES dataset using the Phenopolis bioinformatics pipeline [74]. Reads were aligned to the hg19
human reference sequence (build GRCh37) with NovoAlign (version 3.02.08; Novocraft Technologies,
Petaling Jaya, Malaysia). The aligned reads were sorted by base pair position and duplicates were
marked using NovoSort (version 1.03.05; Novocraft Technologies). Discordant reads were identified
using SAMBLASTER (version 0.1.25) [79]. Variant calling and recalibration were performed using the
Genome Analysis Tool Kit (GATK) (version 3.5) (https://www.ncbi.nlm.nih.gov/pubmed/20644199). As
per the GATK Best Practices, variant calling from the aligned reads was performed using HaplotypeCaller
and joint variant calling was performed using GenotypeGVCFs. Variant Quality Score Recalibration
(VQSR) was performed separately for SNVs and indels to estimate the variant quality score log-odds
(VQSLOD) and the FILTER values per variant.
3. Results
3.1. Exomiser Performance on the Inherited Retinal Disease (IRD) Patient Dataset
We benchmarked Exomiser version 12.0.1 on a dataset of 134 whole-exomes from IRD patients
who had received a molecular diagnosis which included SNVs and/or indels. After applying the
filtering step (Figure 1) (with identical options and values used across all the eight analysis settings,
Table 3), each patient’s exome was found to carry an average number of 474 variants (range 229–1276)
in an average number of 358 genes (range 193–925). The correct diagnosed causative variants (Table S1)
were kept within the filtered variant dataset for all patients, apart from patient P85 (clinically diagnosed
with retinal dystrophy) and patient P94 (clinically diagnosed with retinitis pigmentosa) (“Filtered
out”, Table 4 and Figure 3). Patient P85 had been solved with a homozygous frameshift truncation
variant (Glu211Aspfs*13) in LCA5 gene; this homozygous variant had been detected only via manual
inspection of the sequencing data (at a low covered region) via the Integrative Genomics Viewer (IGV)
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and further experiments. The variant had been instead interpreted as heterozygous by the calling
variant pipeline and therefore did not pass the Exomiser AR mode of inheritance filter. Similarly, for
patient P94, the diagnosed variant had been erroneously called as heterozygous in the VCF file and did
not pass the Exomiser XR mode of inheritance filter.
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“Filtered out/Not prioritized”) per each analysis setting. The right-hand panel shows the corresponding
cumulative percentage distributions.
Using the DEFAULT analysis settings (Table 3), Exomiser was able to assign the correct causative
variants first rank for 99 (74%) IRD patients; the diagnosed mutations were ranked top 5 and top 10
in 94% and 96 of the patients’ exomes, respectively; the median and mean ranks of the causative
variants were 1 and 2.1, respectively (range: 1–42) (Table 4 and Figure 3). For patient P126 (clinically
diagnosed with Usher syndrome type I and molecularly diagnosed as compound heterozygote with
variants in ADGRV1 gene, Table S1), the correct diagnosed gene was ranked first, but only one of the
two diagnosed heterozygous variants was selected as “contributing” to the final Exomiser score (“Not
prioritized”, Table 4 and Figure 3). The best semantic similarities that determined the gene-specific
phenotype scores were obtained from the human disease databases (i.e., OMIM/Orphanet) for 125
(94.7%) exomes out of the 132 exomes for which the correct variants (and corresponding genes) were
not filtered out. The HPO profiles used to annotate the patients’ clinical diagnoses either matched
(to a certain extent) the HPO annotation in OMIM/Orphanet for the same disorder of the patient or a
phenotypically similar one (e.g., retinitis pigmentosa and Bardet-Biedl syndrome 1, OMIM:209900, or
cone-rod dystrophy and Joubert syndrome with ocular defect, ORPHA:220493). As to the remaining of
the IRD dataset, the best phenotype matches were observed with a mouse model for 3 (2.3%) exomes
(with the correct genes ranked 1, 1, and 2) and with a zebrafish model for 1 (0.7%) exome ( ith the
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correct gene ranked 5), and based on data from the protein–protein database for 3 (2.3%) exomes (with
the correct genes ranked 5, 7, and 12).
Table 4. Descriptive statistics of the Exomiser disease-causing variant ranking in the IRD patient dataset
using different analysis settings.
Analysis
Setting
Variants
Filtered out
Variants not
Prioritized a
Mean
Rank (SD)
Median
Rank
Min
Rank
Max
Rank
Top Ranked, %
(N = 134)
1. DEFAULT 2 1(gene rank: 1) 2.1 (5.0) 1 1 42 73.9
2. VAR-ONLY 2 1(gene rank: 30) 10.8 (9.0) 9.5 1 60.5 3.0
3. CADD 2 2(gene ranks: 1, 2) 2.5 (8.4) 1 1 77 72.4
4. REVEL 2 2(gene ranks: 2, 9) 3.9 (9.2) 1 1 78 71.6
5. MPC 2 1(gene rank: 2) 10.1 (16.6) 1 1 79 56.0
6. M_CAP 2 2(gene ranks: 2, 18) 6.8 (12.5) 1 1 64 62.7
7. MVP 2 2(gene ranks: 2, 4) 3.1 (10.3) 1 1 108 76.9
8.
PRIMATE-AI 2
1
(gene rank: 2) 2.7 (5.0) 1 1 33 73.1
a In the case of patients with the disease-causing variants passing the filtering step but not being prioritized (i.e.,
not “contributing” to the final Exomiser score), the ranks given to the correct diagnosed gene are indicated in
parentheses. The mean/median/min/max ranks in the table refer to the effective N, that is 134 − (# of patients with
disease-causing variants filtered out) − (# of patients with disease-causing variants not prioritized).
In order to gain insights into the added value of using the phenotype score in the Exomiser score
calculation (Figure 1), we run the VAR-ONLY analysis using only the variant score (with the same
pathogenicity algorithms as per the DEFAULT settings, i.e., Polyphen-2, MutationTaster, and SIFT)
(Table 3). The correct causative variants were ranked first only for 4 out of 134 patients; while in 27%
and 55% of the patients’ exomes the diagnosed mutations were ranked top 5 and top 10, respectively,
the median and mean ranks of the causative variant(s) were 9.5 and 10.8, respectively (range: 1–60.5)
(Table 4 and Figure 3). The percentage agreement between DEFAULT and VAR-ONLY settings was
only 8% (“poor” κ = −0.013); overall, the DEFAULT settings significantly outperformed the VAR-ONLY
settings (Wilcoxon signed rank test, p-value = 1.0 × 10−20) (Table 5 and Figure 3).
We also run Exomiser using only one of the newly added six pathogenicity algorithms (i.e., either
CADD, REVEL, MPC, M_CAP, MVP, or PRIMATE-AI) to calculate the variant score, together with
the phenotype score to obtain the final Exomiser score as per in the DEFAULT settings (Table 3). The
ensemble CADD and REVEL settings were both able to rank the correct disease-causing variants in
72% of the IRD dataset; similarly, the deep neural network MVP and PRIMATE_AI settings assigned
the diagnosed mutations first rank in 77% and 73% of the dataset (Table 4 and Figure 3). Overall, none
of these four single pathogenicity algorithm-based settings showed a statistically different performance
from the DEFAULT settings (Wilcoxon signed rank test, p-value = 0.195, 0.511, 0.400, and 0.556, for
the comparison of DEFAULT with CADD, REVEL, MVP, and PRIMATE-AI, respectively) with high
percentage agreements (Table 5 and Figure 3). The pairwise DEFAULT-CADD comparison showed
the highest percentage agreement (92%) with a “substantial” κ value equal to 0.80. On the other
hand, despite moderate agreement, the DEFAULT settings mostly outperformed the MPC and M_CAP
settings (Wilcoxon signed rank test, p-value = 7.4 × 10−6 and 0.001, with “fair” κ values equal to 0.24
and 0.27, respectively), where the disease-causing variants were ranked first in 56% and 63% of the
IRD patient dataset, respectively (Figure 3).
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Table 5. Pairwise agreement between Exomiser disease-causing ranking results in the IRD patient dataset using different analysis settings.
DEFAULT vs.
VAR-ONLY Top 2–5 6–10 >10
Filtered
out/Not Prioritized Total
DEFAULT vs.
M_CAP Top 2–5 6–10 >10
Filtered
out/Not Prioritized Total
Top 4 28 28 39 99 Agreement, % Top 74 3 4 18 99 Agreement, %
2–5 3 9 15 27 7.6 2–5 10 9 1 6 1 27 64.6
6–10 1 1 2 Cohen’skappa 6–10 1 1 2
Cohen’s
kappa
>10 1 2 3 −0.013(“poor”) >10 2 1 3 0.27 (“fair”)
Filtered
out/Not
prioritized
3 3 Stuart–MaxwellP
Filtered
out/Not
prioritized
3 3 Stuart–MaxwellP
Total 4 32 38 57 3 134 3.4 × 10−22 Total 84 13 7 26 4 134 8.5 × 10−6
DEFAULT vs.
CADD Top 2–5 6–10 >10
Filtered
out/Not prioritized Total
DEFAULT vs.
MVP Top 2–5 6–10 >10
Filtered
out/Not prioritized Total
Top 93 5 1 99 Agreement, % Top 93 1 1 4 99 Agreement, %
2–5 2 23 1 1 27 92.3 2–5 10 15 1 1 27 84.6
6–10 1 1 2 Cohen’skappa 6–10 1 1 2
Cohen’s
kappa
>10 1 2 3 0.80(“substantial”) >10 1 2 3
0.58
(“moderate”)
Filtered
out/Not
prioritized
1 2 3 Stuart–MaxwellP
Filtered
out/Not
prioritized
3 3 Stuart–MaxwellP
Total 97 28 3 2 4 134 0.818 Total 103 17 2 8 4 134 0.040
DEFAULT vs.
REVEL Top 2–5 6–10 >10
Filtered
out/Not prioritized Total
DEFAULT vs.
PRIMATE_AI Top 2–5 6–10 >10
Filtered
out/Not prioritized Total
Top 85 4 3 7 99 Agreement, % Top 88 3 5 3 99 Agreement, %
2–5 11 12 1 2 1 27 75.4 2–5 10 12 1 3 1 27 79.2
6–10 1 1 2 Cohen’s kappa 6–10 1 1 2 Cohen’skappa
>10 2 1 3 0.40 (“fair”) >10 1 2 3 0.48(“moderate”)
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Table 5. Cont.
DEFAULT vs.
VAR-ONLY Top 2–5 6–10 >10
Filtered
out/Not Prioritized Total
DEFAULT vs.
M_CAP Top 2–5 6–10 >10
Filtered
out/Not Prioritized Total
Filtered
out/Not
prioritized
3 3 Stuart–MaxwellP
Filtered
out/Not
prioritized
1 2 3 Stuart–MaxwellP
Total 96 17 6 11 4 134 0.011 Total 98 16 9 8 3 134 0.011
DEFAULT vs.
MPC Top 2–5 6–10 >10
Filtered
out/Not prioritized Total
Top 66 3 5 25 99 Agreement, %
2–5 9 9 1 7 1 27 59.2
6–10 1 1 2 Cohen’skappa
>10 1 2 3 0.24 (“fair”)
Filtered
out/Not
prioritized
1 2 3 Stuart–MaxwellP
Total 75 13 7 36 3 134 1.0 × 10−7
Table contingency counts represent number of patients at which the corresponding correct diagnosed variants were ranked by two analysis settings. DEFAULT: the Exomiser score was
obtained from the variant score based on allele frequency (as defined in the filtering step, Table 3) and the original pathogenicity algorithms PolyPhen-2 [14], MutationTaster [13], and SIFT
[75] using pathogenicitySources: [POLYPHEN, MUTATION_TASTER, SIFT], plus the gene-specific phenotype score, using hiPhivePrioritiser: {} and omimPrioritiser: {}; VAR-ONLY: as in
DEFAULT analysis setting but using only the variant score, i.e., hiPhivePrioritiser and omimPrioritiser were disabled; CADD/REVEL/MPC/M_CAP/MVP/PRIMATE-AI: as in DEFAULT
analysis setting using both the variant score and the phenotype score but making use of only one of the newly added pathogenicity algorithms at a time to calculate the variant score, e.g.,
pathogenicitySources: [CADD]. Agreement between two analysis settings is summarised by the percentage agreement and Cohen’s kappa and assessed via Stuart–Maxwell test. Cohen’s
kappa values are interpreted according to Landis and Koch’s guidelines (i.e., κ < 0.00 as “poor” agreement, 0.00–0.20 as “slight”, 0.21–0.40 as “fair”, 0.41–0.60 as “moderate”, 0.61–0.80 as
“substantial”, and 0.81–1 as “almost perfect” agreement) [76]. Counts in bold (on the diagonals) represent agreement between two analysis settings (both settings assigned the diagnosed
variants the same rank); counts underlined represent when a row analysis setting performed better than a column analysis setting; and counts in italics represent when a row analysis
setting performed worse than a column analysis setting. Blank cells represent zero counts.
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3.2. Examples of Exomiser Results on the IRD Patient Dataset
Below, we describe some representative examples of the Exomiser results on the IRD patient
dataset along with the main Exomiser output features.
Figure 4 shows a screenshot of the HTML output file (from the DEFAULT analysis) for patient
P127 who was clinically diagnosed with Usher syndrome type II and molecularly diagnosed as
compound heterozygote with frameshift elongation c.920_923dup:p.(His308Glnfs*16) and inframe
deletion c.3832_3834del:p.(Leu1278del) in USH2A gene (Table S1). The correct causative variants were
assigned first rank with an Exomiser score equal to 0.965, obtained from a phenotype score equal to
0.780 and a variant score equal to 0.924. The phenotype score was derived from the phenotype match
of the HPO profile used for Usher syndrome type II patients (Table S2) and OMIM:276901 (i.e., Usher
syndrome, type 2A) as the most similar phenotypic annotation of USH2A found in OMIM via the
PhenoDigm algorithm; Exomiser also reported the phenotype matches (with lower phenotype scores)
found for a mouse mutant (0.496) and a zebrafish mutant (0.346) involving USH2A as well as a human
disease, mouse mutant, and zebrafish mutant of the PDZD7 neighboring gene (0.538) found in the
USH2A interactome via STRING analysis. The variant score 0.924 was obtained as the average of
the variant scores of the frameshift elongation variant (1.0) and the inframe deletion variant (0.849)
that formed the “contributing” compound heterozygous genotype; the frameshift elongation variant
was assigned a variant score equal to 1.0 by default, as it belongs to the internal ClinVar whitelist.
Exomiser also reported two other variants that passed the filtering step (with lower variant scores
than the frameshift elongation and inframe deletion “contributing” variants) (Figure 4). Figure S4
depicts an analogous screenshot of the HTML output file (from the DEFAULT analysis) for patient
P42 who was clinically diagnosed with cone-rod dystrophy and molecularly diagnosed with splice
acceptor variant c.3191-1G>T:p.? and missense variant c.2861A>C:p.(Tyr954Ser) in ABCA4. Exomiser
assigned the correct causative variants first rank with a score equal to 0.998, obtained from a phenotype
score equal to 1.0 and a variant score equal to 0.999. In this case, Exomiser found a perfect phenotype
match between the HPO profile used for cone-rod dystrophy patients (Table S2) and the phenotypic
annotation for OMIM:604116 (i.e., Cone-rod dystrophy 3). Phenotype matches with lower phenotype
scores were also reported for a mouse mutant (0.571) involving ABCA4 and a human disease (i.e.,
Macular dystrophy, vitelliform, 4) associated with the neighboring IMPG1 gene (0.570) in the ABCA4
interactome. The variant score 0.999 was obtained as the average of the variant scores of the two
“contributing” variants that formed the compound heterozygous genotype, i.e., 0.999 for the splice
acceptor variant (predicted to be pathogenic by MutationTaster and with maximum MAF equal to
0.0097% detected in the LOCAL database) and 0.999 for the missense variant (with highest pathogenic
score equal to 1 as predicted by MutationTaster and maximum MAF equal to 0.0097% detected in the
LOCAL database).
Interestingly, the correct disease-causing variants in CLN3, COL18A1, HPS6, and SRD5A3, for
which the corresponding patients had received a new, more syndromic diagnosis following WES
(patients P38, P41, P44, and P50; Table S1), were all assigned either first or second rank (using the
DEFAULT analysis settings) (Table S3). That was the result of high variant scores (0.997, 1.0, 1.0,
and 1.0, respectively) coupled with relatively high phenotype scores (0.798, 0.656, 0.598, and 0.905,
respectively). Remarkably, all the phenotype scores were derived from the phenotype match of the
HPO-encoded patient’s initial diagnosis with the correct (new) diagnosis in OMIM, i.e., OMIM:614075
(Hermansky-Pudlak syndrome 6) associated with HPS6, OMIM:267750 (Knobloch syndrome, type 1)
associated with COL18A1, OMIM:612379 (Congenital disorder of glycosylation, type Iq) associated
with SRD5A3, and OMIM:204200 (Ceroid lipofuscinosis, neuronal, 3; Batten disease) associated with
CLN3, respectively.
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For five patients (4%), the correct disease-causing variants were ranked outside the top 5 candidates
(using the DEFAULT analysis settings): patient P43 (Leber congenital amaurosis; DHX38) with rank 7,
patient P4 (achromatopsia; POC1B) with rank 9, patient P27 (congenital stationary night blindness;
TRNT1) with rank 12, patient P80 (Stickler syndrome; COL9A3) with rank 39, and patient P118 (retinitis
pigmentosa; RP1L1) with rank 42 (Table S1 and Table S4). The low-performing ranking seemed to
derive from the relatively low phenotype scores, i.e., 0.502, 0.500, 0.378, and 0.405 for patients P43, P27,
P80, and P118, respectively, while all the variant scores were relatively high, i.e., 0.997, 0.989, 0.997,
and 0.997, respectively, with the exception of patient P4 where a moderate phenotype score (0.587) is
coupled with a moderate variant score (0.848).
DHX38 had been first associated to IRD (OMIM:618220) with homozygous missense variant
c.995G>A:p.(Gly332Asp) found in four affected sibs from a consanguineous Pakistani family with
early-onset retinitis pigmentosa and macular coloboma [80] and, more recently, has been confirmed
to cause early-onset retinitis pigmentosa in two consanguineous Pakistani families with early-onset
retinitis pigmentosa [81] with same homozygous missense variant c.971G>A:p.(Arg324Gln) also seen
in patient P43 (Leber congenital amaurosis; rank 7) from the IRD dataset in this analysis. Exomiser
did not identify any known gene-phenotype annotations in human disease (Table S4) as the current
version of the Exomiser phenotype database does not contain yet the OMIM:618220 phenotypic
annotation for DHX38. Nevertheless, Exomiser detected some phenotypic similarity (0.502) of patient
P43 with the OMIM:231550 (Achalasia-addisonianism-alacrimia syndrome) phenotypic annotation of
the neighboring AAAS gene in the DHX38 interactome. For patient P4 (achromatopsia; POC1B; rank
9), one of the two patient’s HPO profile terms, i.e., “Achromatopsia” (HP:0011516), was deemed to be
moderately similar (0.587) with the phenotypic annotation “Abnormality of color vision” (HP:0000551)
in OMIM:615973 (Cone-rod dystrophy 20; POC1B); the other patient’s HPO profile term, i.e., “Abnormal
light-adapted electroretinogram” (HP:0008275), did not match any HPO term in OMIM:615973. In
addition to that, for the diagnosed POC1B inframe deletion variant c.130_138del:p.(Ile44_Leu46del),
no pathogenic data were available and a preset value of 0.85 was used, resulting in a moderate
variant score (0.848). Similarly, for patient P27 (congenital stationary night blindness; TRNT1; rank 12),
the phenotypic similarity of the patient with OMIM:616959 (Retinitis pigmentosa and erythrocytic
microcytosis) was modest (0.476), and the best phenotypic similarity, still moderate (0.500), was found
with the phenotypic annotation of the neighboring RP9 gene (associated with Retinitis pigmentosa 9)
in the TRNT1 interactome. Finally, for patient P80 (COL9A3) and patient P118 (RP1L1), Exomiser found
that the observed AR mode of inheritance of the “contributing” variants were incompatible with the
reported OMIM mode of inheritance of the corresponding best phenotype match (AD OMIM:600969
and AD OMIM:613587, respectively). The fact that COL9A3 is also annotated as AR in Orphanet
(ORPHA:250984, Stickler syndrome) is not taken into account in the current implementation of the
omimPrioritiser option. As a result of that, the otherwise high phenotype scores were halved as per
Exomiser settings (from 0.755 to 0.378 and from 0.809 to 0.405, respectively).
4. Discussion
We used the latest version of the bioinformatics tool Exomiser to perform phenotype-driven
variant prioritization analysis of whole-exome data to evaluate its performance in molecular diagnosis
for rare Mendelian disease. Earlier published software versions had been tested primarily on simulated
whole-exome data [37,59]. In contrast, we assessed the software performance using a real patient,
whole-exome dataset from 134 patients affected by IRD with a known molecular diagnosis. Exomiser
ranked the correct diagnosed variants as the top candidate in three out of four whole-exomes in the
IRD dataset (using the DEFAULT analysis settings, Table 3) and within the top 5 candidates in up to
94% of the dataset (Table 4 and Figure 3).
At the core of the Exomiser analysis framework, there is the use of a phenotype score that evaluates
how similar an HPO-encoded rare disease patient’s phenotype is with any known gene-phenotype
annotations in human, mouse, and zebrafish. This is in addition to standard variant prioritization based
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on variant rarity and predicted pathogenicity (Figure 1). Running the analysis without making use of
the Exomiser phenotype score (VAR-ONLY analysis settings, Table 3) showed a substantial decrease in
performance with an unsatisfactory disease-causing variant ranking: the correct diagnosed variants
were scored as top candidate in only 3% of the dataset and up to 27% within the top 5 candidates. The
success of Exomiser in prioritizing disease-causing variants is dependent on accurate HPO terms that
encode the patient’s phenotype, and this may be challenging in a busy clinical context. Our method of
encoding the patient’s clinical diagnoses into a fixed list of HPO terms proved to be effective; however,
many tools and platforms now exist that facilitate the efficient collection of patients’ HPO-encoded
clinical phenotypes and/or automated extraction of human disease phenotypes from free text clinical
notes as well as electronic health records [82–85].
Given the nature of the solved IRD exome dataset, with most diagnosed genes being either
established retinal genes or published over the recent years, we expected the human disease databases
contributing the most to the gene-specific phenotype scoring. For 125 (95%) exomes out of the 132
exomes for which the correct variants (and corresponding genes) were not filtered out (using the
DEFAULT settings, Tables 3 and 4), the best phenotype matches were obtained with an OMIM/Orphanet
human disorder, either the same disorder of the patient or a phenotypically similar one (the latter
case showing the flexibility of a semantic similarity method over the use of a fixed panel of candidate
genes/diseases). Nevertheless, for the remaining 5% of the exomes where the best phenotype matches
were based on mouse/zebrafish model or protein–protein interaction data, the correct diagnosed
genes were still ranked rather effectively (i.e., 1, 1, 2, 5, 5, 7, and 12). For example, the diagnosed
variant in DHX38 seen in patient P43 (Table S1 and Table S4) was assigned rank 7, despite this recently
published disease-gene association not yet being included in the underlying human disease databases.
Furthermore, we run a new analysis with same settings as per DEFAULT, but without using the human
disease databases for the phenotype scoring. Despite the expected reduced performance in comparison
with the full DEFAULT analysis, we observed a good software performance: Exomiser was able to
assign the correct causative variants first rank for 82 (61%) IRD patients; the diagnosed mutations were
ranked top 5 and top 10 in 80% and 87% of the patients’ exomes, respectively, with the median and
mean ranks of the causative variants equal to 1 and 5.9, respectively (range: 1–69). This clearly shows
the ability of Exomiser to assist the discovery of novel disease genes due to the incorporation of model
organism and protein–protein interaction data.
The original benchmarking of Exomiser performed on 10,000 simulated rare disease whole-exomes
showed that up to 97% of the data received the top scoring hit for the correct causative variants [59].
Despite the fact that a fair comparison is not possible due to the different software releases, it can be noted
that the performance of Exomiser reduced by about 24% (for the first rank, using the DEFAULT analysis
settings; Table 3, Table 4, and Figure 3) when using the real patient IRD dataset presented in this analysis.
That may somewhat be expected due to the likely inherently more complex nature of real patient data;
also, to describe the phenotypes of the simulated exomes, the authors used perfect HPO term matching
derived from OMIM for each disease, and that might have affected the good performance. On the same
line, given that Exomiser was originally benchmarked using PolyPhen-2, MutationTaster, and SIFT as
pathogenicity sources, our software performance estimates based on the use of each of the newly added
pathogenicity algorithms one at a time (i.e., CADD/REVEL/MPC/M_CAP/MVP/PRIMATE-AI analysis
settings, Table 3) should be regarded as an exploratory assessment of how well the new pathogenicity
scores perform with the existing Exomiser framework rather than a direct comparison of how effective
each scoring system is.
Notably, for all the four patients that had received a new (more syndromic) diagnosis based on the
findings from their WES data and further clinical examination (patients P38, P41, P44, and P50; Table
S1), Exomiser not only provided an excellent prioritization of the correct diagnosed variants (i.e., first
rank for three patients and second rank for one patient, using the DEFAULT analysis settings, Table 3)
but also, remarkably, unveiled the phenotype matches with the correct new diagnoses. These findings
show the ability of Exomiser to support unbiased and efficient differential diagnostics based on the
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automated interpretation of sequencing data in the context of known human disease gene-phenotype
databases. Presenting such prioritized results can potentially trigger further patient clinical examination
and can lead to faster molecular diagnosis together with more appropriate patient management.
On the other hand, Exomiser failed to prioritize the correct diagnosed variants as the top 5
candidates for five (4%) patients (i.e., ranks 7, 9, 12, 39, and 42, using the DEFAULT analysis settings,
Table 3). That was generally due to incompleteness or inaccuracy of the disease and phenotype databases
used in the analysis. Exomiser and similar approaches should not be regarded as tools for perfect
automation of the variant prioritization process but rather aids to support the lengthy, multidisciplinary
effort carried out by various clinicians, scientists, and analysts to pinpoint disease-causing variants.
Nevertheless, as these databases are continuously updated, prioritization is expected to improve [86].
Another limitation of Exomiser consists in its current inability of incorporating CNVs in the analysis of
SNVs and indels from VCF files. CNVs have been implicated in various diseases such as autoimmune
and neuropsychiatric disorders [87] and are expected to explain part of the rare disease patients without
a genetic diagnosis. Future Exomiser releases will be extended to include CNV analysis functionality.
The sample size of the IRD dataset used in this analysis (i.e., 134) is among the largest real
patient tested with phenotype-driven prioritization tools. Nevertheless, it would be desirable to
test larger datasets on a broader range of rare Mendelian diseases to achieve more accurate and
definite insights into Exomiser software performance. Indeed, Exomiser has been already adopted in
many sequencing data analysis pipelines to support the identification of Mendelian disease-causing
variants [88–95]. Exomiser can also efficiently process whole-genome sequencing samples (in about
5 minutes if only coding data are analyzed and in about 20 minutes for both coding and noncoding
data) and is now routinely used in the variant interpretation pipeline of the 100,000 Genomes Project
(https://www.genomicsengland.co.uk/) [96].
Many other HPO-driven variant prioritization tools exist [34–52], all primarily tested only on
(different) simulated datasets with limited software performance comparison. Further work should
include a systematic and exhaustive software performance comparison on both simulated and real
patient large datasets. Before embarking in such task, a thorough literature review is warranted
to identify the tools that could be feasibly used (e.g., freely available, with command-line access,
reasonably maintained, and/or recently updated).
In conclusion, using real patient data with known molecular diagnosis, we showed how Exomiser
is an effective variant prioritization tool for the integrative analysis of rare Mendelian HPO-encoded
clinical phenotypes and whole-exomes. We recommend using Exomiser as an effective bioinformatics
tool to support and speed up whole-exome sequencing data analysis for molecular diagnostics in rare
Mendelian disease.
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